PDMR Dealing

Oxford Biomedica PLC

19 May 2026

 

PDMR Dealing

Oxford, UK - 19 May 2026: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Kathleen Miller has exercised 4,486 Restricted Share Units ("RSU") options granted under the 2024 Long Term Incentive Plan ("2024 LTIP Plan") at an exercise price of £nil on 18 May 2026 and disposed of 1,578 ordinary shares at an average price of £6.091 per share on 18 May 2026.

The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")
a)	Is this a PDMR or PCA submission	Submission for PDMR
b)	Name of natural person	Kathleen Miller
c)	Legal person
2.	Reason for the notification
a)	Position/status	Head of Human Resources (and acting Interim Site Head, Bedford Operations)
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	18-May-2026
b)	Description of the financial instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Nature of the transaction	Exercise of 4,486 RSUs under 2024 LTIP Plan
e)	Place of the transaction	Outside the trading venue
f)	Currency	GBP - British pound
g)	Price(s) and volumes(s)	Price(s) Volume(s) 0.00 4,486
h)	Aggregated information -    Aggregate volume -    Price -    Aggregated total	4,486 £0.00 £0.00

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")
a)	Is this a PDMR or PCA submission	Submission for PDMR
b)	Name of natural person	Kathleen Miller
c)	Legal person
2.	Reason for the notification
a)	Position/status	Head of Human Resources (and acting Interim Site Head, Bedford Operations)
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	18-May-2026
b)	Description of the financial instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Nature of the transaction	Sale of 1,578 ordinary shares
e)	Place of the transaction	London Stock Exchange, Main Market (XLON)
f)	Currency	GBP - British pound
g)	Price(s) and volumes(s)	Price(s) Volume(s) £6.091 1,578
h)	Aggregated information -    Aggregate volume -    Price -    Aggregated total	1,578 £6.091 £9,611.60

-Ends-

Enquiries:       

OXB:

Natalie Walter, Chief Legal Officer and Group Company Secretary - T: [phone] / E: [e-mail]

ICR Healthcare:

T: [phone] / E: [e-mail]

Mary-Jane Elliott / Sarah Elton-Farr / Angela Gray

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.

 

END